MARKET

VRNA

VRNA

Verona Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.650
-0.110
-2.31%
Closed 16:00 06/01 EDT
OPEN
4.780
PREV CLOSE
4.760
HIGH
4.890
LOW
4.458
VOLUME
35.37K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
2.010
MARKET CAP
61.74M
P/E (TTM)
-1.3705
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VRNA stock price target is 27.33 with a high estimate of 50.00 and a low estimate of 8.00.

EPS

VRNA News

More
60 Biggest Movers From Yesterday
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares surged 71.1% to close at $15.21 on Thursday after the company announced it has received FDA emergency use authorization for its coronavirus diagnostic assay kit.
Benzinga · 05/15 08:53
RIOT, WIX among premarket gainers
Seeking Alpha - Article · 05/14 13:14
32 Stocks Moving in Thursday's Pre-Market Session
Gainers BioPharmX Corporation (NYSE: BPMX) shares rose 56.4% to $0.73 in pre-market trading after the company reported approval of merger with Timber Pharma by shareholders.
Benzinga · 05/14 11:15
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) announces that it has received written comments from the U.S. Food and Drug Administration (FDA) in response to its End-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic ob
Benzinga · 05/14 09:39
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
The response supports Verona Pharma progressing with its planned Phase 3 clinical program, which is expected to start later in 2020. It is planned to be called the ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) program.
GlobeNewswire · 05/14 06:00
Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings
GlobeNewswire · 05/12 13:11
Molina Magellan Purchase, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/05 10:09
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/02 01:24

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About VRNA

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.
More

Webull offers kinds of Verona Pharma Plc stock information, including NASDAQ:VRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRNA stock news, and many more online research tools to help you make informed decisions.